Balyasny Asset Management
ACET icon

Balyasny Asset Management’s Adicet Bio ACET Stock Holding History

Balyasny Asset Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-386,354
Closed -$14.5M – 2508
2024
Q1 		$14.5M Buy
+386,354
New +$16M 0.03% 773
2023
Q4 		– Sell
-784
Closed -$17.2K – 2432
2023
Q3 		$17.2K Buy
+784
New +$27.7K ﹤0.01% 2179
2023
Q2 		– Sell
-1,722
Closed -$159K – 2219
2023
Q1 		$159K Buy
1,722
+296
+21% +$37.1K ﹤0.01% 2263
2022
Q4 		$204K Buy
+1,426
New +$356K ﹤0.01% 2130

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Balyasny Asset Management's ACET Position: Q2 2024 in Review

Balyasny Asset Management sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 386,354 shares — an estimated $14.5M sold.

Balyasny Asset Management first reported a position in ACET in Q4 2022 and held it in 4 quarters. The position peaked at $14.5M in Q1 2024. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Balyasny Asset Management reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 386,354 Adicet Bio shares in Q2 2024, an estimated $14.5M.
  • Balyasny Asset Management first reported a position in Adicet Bio in Q4 2022 and held it in 4 quarters.
  • Balyasny Asset Management's Adicet Bio position peaked at $14.5M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.